3 research outputs found
Recommended from our members
Implementing NMC standards for learning, and assessing in practice(2006): a demonstration of effective partnership between a higher education institution and NHS Trust placement partners
This paper provides an account of the collaborative approach taken to implement professional standards in teaching, learning and assessing in practice for nursing and midwifery. How challenges for effective partnership working between university and placement/practice education provider were overcome are presented. Processes and issues which arose when new national regulatory professional standards of practice education were introduced are highlighted.
The partnership work ensured a robust process to locally interpreting and implementing the NMC Standards for Supporting Learning and Assessing in Practice (2006). This was achieved and resulted in a county wide agreed implementation of the Standards across NHS Oxfordshire and beyond.
The key requirements of the Standards and the challenges identified are presented together with how issues were addressed.
The approach taken by an established partnership working group is described and the products of the process are detailed, including listing 'top tips' for successful partnership working
Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice
Global containment of COVID-19 still requires accessible and affordable vaccines for low- and middle-income countries (LMICs). Recently approved vaccines provide needed interventions, albeit at prices that may limit their global access. Subunit vaccines based on recombinant proteins are suited for large-volume microbial manufacturing to yield billions of doses annually, minimizing their manufacturing cost. These types of vaccines are well-established, proven interventions with multiple safe and efficacious commercial examples. Many vaccine candidates of this type for SARS-CoV-2 rely on sequences containing the receptor-binding domain (RBD), which mediates viral entry to cells via ACE2. Here we report an engineered sequence variant of RBD that exhibits high-yield manufacturability, high-affinity binding to ACE2, and enhanced immunogenicity after a single dose in mice compared to the Wuhan-Hu-1 variant used in current vaccines. Antibodies raised against the engineered protein exhibited heterotypic binding to the RBD from two recently reported SARS-CoV-2 variants of concern (501Y.V1/V2). Presentation of the engineered RBD on a designed virus-like particle (VLP) also reduced weight loss in hamsters upon viral challenge